How to Buy C4 Therapeutics Stock
C4 Therapeutics Inc
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
C4 Therapeutics stock last closed at $1.70, down 8.6% from the previous day, and has decreased 80.44% in one year. It has underperformed other stocks in the Biotechnology industry by 0.46 percentage points. C4 Therapeutics stock is currently +1.19% from its 52-week low of $1.68, and -83.69% from its 52-week high of $10.42.
As of Oct 2, 2023, there are 49.19M CCCC shares outstanding. The market value of CCCC is $83.62M. In the last 24 hours, 440,375 CCCC shares were traded.
How to Buy C4 Therapeutics Stock
Wondering how to invest in C4 Therapeutics stock? Here's how.
- Figure out where to buy C4 Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy C4 Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit money your brokerage account: Select your payment method and add your details.
- Evaluate C4 Therapeutics stock: The C4 Therapeutics ticker symbol is CCCC. Is C4 Therapeutics stock a good investment? Should you buy shares of CCCC? How do CCCC's underlying business fundamentals look? Do top analysts think C4 Therapeutics is a good buy? Why has CCCC's stock price moved recently? (Hint: Our stock market analysis website can help you decide if CCCC is a good stock to buy).
- Execute your CCCC purchase: Decide if you will purchase CCCC shares at the current market price or use a limit order to purchase CCCC stock at a specific price.
- Watch your CCCC investment: Create a watchlist to keep track of your new investment in C4 Therapeutics stock.
Step 1: Figure out where to buy C4 Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy CCCC stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Energy, New York to Shanghai — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal details so you can buy CCCC today.
How to Start a New Account on eToro
- Click here to get started.
- Enter your personal info to create a new brokerage account.
- Submit your info by hitting the "Create Account" button.
Step 3: Deposit money your brokerage account
Now that you've filled out your info on our top ranked stock trading app, you can securely and quickly fund your account:
Check out the tutorial below if you need help depositing funds into your new investment account.
Step 4: Evaluate C4 Therapeutics stock
Once you have chosen the best place to buy C4 Therapeutics stock, it's absolutely critical to research their stock prior to investing, so you actually comprehend the risk and upside.
C4 Therapeutics shares data
C4 Therapeutics Fundamentals
WallStreetZen was built to help part-time investors do more accurate fundamental analysis in less time.
You can view all of the due diligence checks on CCCC's stock page.
Is CCCC stock overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CCCC's fair value.
Using relative valuations methods:
- CCCC may be undervalued based on its P/B ratio of 0.36x, relative to Biotechnology industry P/B ratio of 5.05x
You can access more valuation research on CCCC's stock here.
CCCC Financial Health Summary
Passed Financial Due Diligence Checks:
- CCCC has $270.56M in cash and short term investments. This is sufficient to cover its annual cash burn of $115.02M.
- There are more short-term assets than long-term liabilities on the CCCC balance sheet.
- There are more short-term assets than short-term liabilities on the CCCC balance sheet.
- CCCC has cash burn of 115016000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- CCCC has a relatively high debt to equity ratio of 0.61.
- CCCC profit margin has gone down from -198.5% to -872.3% in the past year.
Is it a good time to buy C4 Therapeutics stock, according to analysts?
Out of 3 Wall Street analysts who monitor CCCC, the consensus analyst rating on C4 Therapeutics is a Hold
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent CCCC Analyst Upgrades/Downgrades
Andrew Fein, a bottom 1% analyst from HC Wainwright & Co. maintains CCCC with a buy rating and lowers their CCCC price target from $25.00 to $17.00, on Aug 9, 2023.
Gavin Clark-Gartner, a bottom 17% analyst from Evercore ISI Group maintains CCCC with a buy rating and lowers their CCCC price target from $20.00 to $10.00, on May 30, 2023.
Terence Flynn, a top 8% analyst from Morgan Stanley maintains CCCC with a strong sell rating and lowers their CCCC price target from $5.00 to $3.00, on May 12, 2023.
You can dig deeper into what analysts are projecting on the C4 Therapeutics stock forecast page.
CCCC Momentum
How is CCCC performing as a company?
Last year, CCCC revenue was $16.03M. Over the last three year, CCCC's revenue has increased by -77.57% per year. This was slower than the Biotechnology industry average of 107.76%.
You can research CCCC's earnings and revenue performance here.
Latest Insiders Trades at CCCC
In the past 12 months, executives and large shareholders at CCCC have bought more shares than they have sold.
Scott N. Boyle, Chief Business Officer of CCCC, was the latest CCCC insider to sell. They sold $1,936.73 worth of CCCC stock on Aug 30, 2023.
Learn more about who owns CCCC stock here.
Does CCCC provide a stable income stream?
No, C4 Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about CCCC?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your CCCC purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the best for newer investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount, use a limit order.
Click the Open Trade button and your broker will execute your order.
If you require additional assistance buying stocks on eToro, click the how to video below:
Step 6: Watch your CCCC investment
Now that you own some CCCC stock, you'll want to keep up with your new shares.
Create a watchlist to keep track of your CCCC stock.
CCCC Feed
How to Buy Stock in C4 Therapeutics
To summarize, here are the 6 steps for buying C4 Therapeutics stock:
- Figure out where to buy C4 Therapeutics stock
- Sign up for a brokerage account
- Deposit money your brokerage account
- Evaluate C4 Therapeutics stock
- Execute your CCCC purchase
- Watch your CCCC investment
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to track your new investment in C4 Therapeutics, add CCCC to your watchlist by clicking the button below.
Other Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.